Clinical trials: Digestive Tract Diseases
Parkinson Disease, Depression
Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease
This study evaluates the use of an oral multi-strain probiotic in the treatment of depression in individuals with Parkinson's Disease.
- Conditions
- Parkinson Disease, Depression, PARKINSON DISEASE (Disorder)
- Trial name
- ProD (NCT05568498)
- Testing
- Probiotic
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University of British Columbia
Biliary Disease
Microbiology in Obstructive BIliary Disease
Patients admitted to hospital due to obstructive biliary disease secondary to benign and malign etiologies, undergoing ERCP, will be selected. Bile sample will be taken in ERCP procedure with sterile technique.
- Trial name
- NCT05464693
- Testing
- ERCP biliary culture
- Where
- Mexico
- Volunteers
- 70 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Lung Cancer, Esophageal Cancer
Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers
Other than optimizing medical management of cardiac risk factors, and reducing radiotherapy (RT) dose to the heart, there currently exist no interventions to mitigate or reverse the adverse cardiac effects of RT.
- Conditions
- Lung Cancer, Esophageal Cancer, Thoracic Cancer, Hodgkin Lymphoma
- Trial name
- NCT04072393
- Testing
- Home-based cardiac rehabilitation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Breast Cancer, Colorectal Cancer
Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer
The main objective of study is to describe the priorities of elderly patients (70 years and over) undergoing a first medical treatment for cancer, at initiation of treatment and after 3 months of treatment.
- Conditions
- Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer
- Trial name
- PRIORITY (NCT02821793)
- Testing
- Consultation, evaluation questionnaire, Geriatric consultation, evaluation questionnaire
- Where
- France
- Volunteers
- 346 people
- Sponsor
- Institut Bergonié
HIV, Atherosclerosis
Effectiveness of Gut Microbiota-targeted Diatery Intervention Among People Living With HIV
The goal of this clinical trial is to conduct a dietary intervention targeting HIV specific gut microbiota alterations for primary atherosclerotic cardiovascular disease (ASCVD) prevention and evaluate its effectiveness in…
- Conditions
- HIV, Atherosclerosis, Diet, Healthy
- Trial name
- NCT06498401
- Testing
- gut microbiota-targeted dietary intervention
- Volunteers
- 110 people
- Sponsor
- Fudan University
Cystic Fibrosis, Oxidative Stress
Flaxseed Modulates Inflammation and Oxidative Stress in CF
Flaxseed (FS) is a safe and well tolerated supplement with an ability to fight inflammation and oxidative stress - a byproduct of daily stress the human body faces everyday and especially with chronic diseases.
- Conditions
- Cystic Fibrosis, Oxidative Stress, Inflammation
- Trial name
- NCT02014181
- Testing
- finely ground flaxseed powder
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Obesity
Inulin-type Fructans-rich Vegetables, Obesity, Gut Microbiota
The purpose of the study was to evaluate the effect of a diet based on ITF-rich vegetables in combination with purified ITF supplementation on weight management, metabolic alteration and gut microbiota composition.
- Trial name
- Food4Gut (NCT03852069)
- Testing
- Inulin
- Volunteers
- 106 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Cholelithiases
Enhanced Recovery After Cholecystectomy
this study will be conducted involving patients of all genders between the ages of 20 and 60 years who will undergo elective laparoscopic cholecystectomy for uncomplicated symptomatic gallstone disease.
- Trial name
- NCT06339437
- Testing
- ERAS Protocol
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Children Hospital and Institute of Child Health, Lahore
Advanced Solid Tumors
A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours
This is a phase I, open-label, multicentre study of MEDI4736 administered intravenously with a standard 3+3 dose-escalation phase to evaluate safety, tolerability, and pharmacokinetics in patients with advanced solid tumor…
- Trial name
- NCT01938612
- Testing
- MEDI4736, tremelimumab
- Where
- 21 sites in Japan, South Korea and 1 more
- Volunteers
- 269 people
- Sponsor
- AstraZeneca
Respiratory Tract Diseases, Abnormal Mucus Secretions
A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
This is a phase 3, multicenter, randomized, rater- and patient-blind, placebo- and active-controlled, 3-arm parallel group clinical trial.
- Trial name
- NCT03843541
- Testing
- N-acetylcysteine (NAC) 600 mg, Ambroxol hydrochloride 30 mg
- Where
- 32 sites in China
- Volunteers
- 333 people
- Sponsor
- Zambon SpA
Cystic Fibrosis
Extension Study of Ataluren (PTC124) in Cystic Fibrosis
Cystic fibrosis (CF) is a genetic disorder caused by a mutation in the gene that makes the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
- Trial name
- NCT01140451
- Testing
- Ataluren
- Where
- 31 sites in United States, Belgium and 9 more
- Volunteers
- 191 people
- Sponsor
- PTC Therapeutics
Anal Cancer, Colorectal Cancer
Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal (GI) Cancer Patients
Primary Objectives: To determine the feasibility of a study that would describe changes of certain circulating inflammatory cytokines (interleukin-1, 6, 8, 10, 12, and tumor necrosis factor-alpha [TNF] and symptoms related to…
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00502502
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 205 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Solid Tumor, Colorectal Cancer
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors.
- Conditions
- Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer
- Trial name
- NCT04579757
- Testing
- Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2
- Where
- 18 sites in United States
- Volunteers
- 87 people
- Sponsor
- Hutchmed
Primary Biliary Cholangitis
Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC
Study to evaluate the efficacy, safety, and tolerability of investigational drug obeticholic acid (OCA) in combination with the investigational drug bezafibrate (BZF) in participants with Primary Biliary Cholangitis (PBC).
- Trial name
- NCT04594694
- Testing
- Obeticholic acid, Bezafibrate 200 MG, Bezafibrate 400 MG
- Where
- 33 sites in Australia, Belgium and 15 more
- Volunteers
- 75 people
- Sponsor
- Intercept Pharmaceuticals
Gut Health
Effectiveness of a Butyrate Formulation and Butyrate + Polyphenol Formulation on Gut Health, Permeability and Associated Symptoms
The purpose of this study is the assess the effectiveness and safety of a Butyrate formulation and a Butyrate + Polyphenol formulation on gut health, permeability and associated symptoms
- Trial name
- NCT06419231
- Testing
- Butyrate Formulation, Butyrate + Polyphenol Formulation
- Where
- United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Supplement Formulators, Inc.
IgA Nephropathy (IgAN)
Exploring the Brain - Gut Microbiota - Kidney Interactive Damage Mechanisms Underlying Cognitive Decline in Patients With IgA Nephropathy Using Ultra-high Field Magnetic Resonance Imaging
IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide. Its progression is often accompanied by cognitive decline, manifesting as multi-dimensional cognitive deficits in areas such as memory, attention…
- Trial name
- NCT07617402
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tang-Du Hospital
Wasting, Undernutrition
Improvement of Nutrition Status, Digestive Conditions, and Upper Respiratory Infections by Using Oral Nutritional Supplementation on Children in Vietnam
Evaluating the efficiency of using the nutrient production toward nutrition status (anthropometric index, the prevalence of wasting), digestive disorders, anorexia, and upper respiratory infections in children aged 24 - 71 months.
- Conditions
- Wasting, Undernutrition, Malnourished, Malnutrition
- Trial name
- NCT05570045
- Testing
- Colos Gain
- Where
- Vietnam
- Volunteers
- 600 people
- Sponsor
- Tu Nguyen Song
Cystic Fibrosis
GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis
This is a Phase IIa, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate GLPG2737 administered orally b.i.d.
- Trial name
- PELICAN (NCT03474042)
- Testing
- GLPG2737
- Where
- 9 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Lakefront Biotherapeutics NV
Obesity
Gut Microbiota Changes in Obese Individuals Undergoing Dedicated Lifestyle Modification Programs
The human gut microbiota has become the subject of extensive research in recent years, particularly in regards to the role it plays in obesity.
- Trial name
- NCT02855242
- Testing
- Lifestyle Counseling, Controls Group
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Cystic Fibrosis Related Diabetes, Cystic Fibrosis
Ivacaftor (Kalydeco) and Insulin in Cystic Fibrosis (CF)
This study is aimed at better understanding the impact of ivacaftor upon insulin and incretin secretion and glucose tolerance in patients with Cystic Fibrosis with a glycine (G551D) mutation.
- Trial name
- NCT02039986
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital of Philadelphia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.